Invivyd News

HC Wainwright & Co. Reiterates Buy on Invivyd, Maintains $15 Price Target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Invivyd (NASDAQ:IVVD) with a Buy and maintains $15 price target.

BenzingaMay 15 00:35

Invivyd Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 532.91% HC Wainwright & Co. → $15 Reiterates Buy → Buy 04/05/2024 279.75% Guggenheim → $9 Upgra

BenzingaMay 15 00:33

Strong Buy Rating for Invivyd Amidst Potential EUA Approval and Promising Revenue Projections

TipRanksMay 14 18:21

Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that Marc Elia,

GlobeNewswireMay 14 04:01

With 31% Stake, Invivyd, Inc. (NASDAQ:IVVD) Seems to Have Captured Institutional Investors' Interest

Yahoo FinanceMay 12 21:28

Earnings Call Summary | Invivyd(IVVD.US) Q1 2024 Earnings Conference

The following is a summary of the Invivyd, Inc. (IVVD) Q1 2024 Earnings Call Transcript:Financial Performance:Invivyd ended Q1 2024 with cash and cash equivalents of $189.4 million.The company did not

Futu NewsMay 12 09:04 · Conference Call

Invivyd Inc (IVVD) Reports Q1 2024 Financial Results: A Detailed Analysis

Yahoo FinanceMay 11 03:25

Invivyd (IVVD.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -0.38 dollars, previous value was -0.32 dollars, and expected value was -0.38 dollars.

Invivyd (IVVD.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -0.38 dollars, previous value was -0.32 dollars, and expected value was -0.38 dollars.

Zhitong FinanceMay 10 06:50

Invivyd | 10-Q: Quarterly report

Futu NewsMay 10 04:53 · Announcements

Invivyd 1Q Loss/Shr 38c >IVVD

Invivyd 1Q Loss/Shr 38c >IVVD

Dow JonesMay 10 04:08

Press Release: Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights -- Launched PEMGARDA(TM) in the U.S. for COVID-19 pre-exposure prophylaxis (PrEP) in certain adults and ad

Dow JonesMay 10 04:01

Invivyd To Pursue Rapid Immunobridging Pathway To Potential EUA For Treatment Of COVID-19 In Moderately To Severely Immunocompromised People, Based On U.S. FDA Feedback

Invivyd To Pursue Rapid Immunobridging Pathway To Potential EUA For Treatment Of COVID-19 In Moderately To Severely Immunocompromised People, Based On U.S. FDA Feedback

BenzingaMay 7 19:39

Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights

WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a

GlobeNewswireMay 3 05:13

Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

Improvements realized through comprehensive resource realignment ensuring robust investment in the commercial launch of PEMGARDATM and the discovery of novel monoclonal antibodiesCompany now expects to end 2024 with at

GlobeNewswireApr 30 19:30

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes From the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA

Product-specific Q Code (Q0224) facilitates product reimbursement for PEMGARDA; corresponding M Code (M0224) defines reimbursement for product administrationReimbursement through Medicare/Medicaid represents

GlobeNewswireApr 15 19:30

Invivyd Reveals CEO Transition; Appoints Jeremy Gowler As Interim CEO, Effective Immediately, To Succeed Dave Hering

Invivyd Reveals CEO Transition; Appoints Jeremy Gowler As Interim CEO, Effective Immediately, To Succeed Dave Hering

BenzingaApr 12 19:33

Invivyd: Gowler Succeeds Dave Hering in the Role>IVVD

Invivyd: Gowler Succeeds Dave Hering in the Role>IVVD

Dow JonesApr 12 19:31

Press Release: Invivyd Announces CEO Transition

Invivyd Announces CEO Transition Jeremy Gowler appointed Interim CEO WALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to prot

Dow JonesApr 12 19:30

Invivyd Appoints Jeremy Gowler Interim CEO >IVVD

Invivyd Appoints Jeremy Gowler Interim CEO >IVVD

Dow JonesApr 12 19:30

Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Invivyd (IVVD)

TipRanksApr 9 00:10